Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Legislation topic
No spam. Unsubscribe anytime.
Board discusses bills on compounding advertising and stipulated settlements; maintains watch while seeking clarifications
Summary
Members debated AB1990 (compounding/advertising) and AB2141 (pre‑accusation stipulated settlements) on June 24; the board shifted AB1990 to a watch posture pending author amendments and sought additional Attorney General Office input and clarifying amendments on AB2141 before taking a formal position.
The California State Board of Pharmacy reviewed multiple bills on June 24 and focused discussion on two items that drew extended public comment and legal concern.
AB 1990, as amended, would restrict sale and advertising of compounded medications containing certain GLP‑1 or related substances used for weight‑management and would add requirements for bulk drug verifications, recordkeeping, and penalties. Board staff and legislators worked with stakeholders to narrow the proposal; the author canceled a committee hearing to consider amendments. The committee recommended returning the board to a watch position so staff can monitor subsequent changes. Stakeholders representing the compounding industry urged transparency in advertising but warned that importing FDA approved labeling verbatim into compounded product advertising could be impractical and pose enforcement challenges.
AB 2141 would permit pre‑accusation stipulated settlements and disciplinary orders under certain conditions, creating an alternative pathway to the current accusation‑then‑settlement process. Board legal counsel and members raised concerns about due‑process implications (requiring a waiver of Administrative Procedure Act hearing rights), the committee’s statutory role, the potential need for AG involvement, and limitations on negotiating counteroffers. Supporters from compounding pharmacy groups said a pre‑accusation settlement pathway would reduce time and cost burdens that threaten patient access to specialized compounded products. The board voted to seek further input from the Attorney General’s Office and engage with the author to refine statutory language rather than adopt an immediate position.
Board staff said they will continue to monitor both bills, work with authors’ offices on technical amendments where appropriate, and return with recommendations as legislative language evolves.
